Researchorganoidshipsctoxicity profilingpersonalized medicine
iXCells Forms Collaboration To Evaluate Chemotherapy Toxicity
6.1
Relevance Score
iXCells Biotechnologies on March 25, 2026 announced an international collaboration with Rosebud Biosciences, Kantify, and Incite to evaluate off‑target chemotherapeutic toxicities using patient‑specific organoids. The partners will reprogram a liposarcoma patient's PBMCs into hiPSCs, generate heart, liver, and kidney organoids, and apply Kantify's investigational compounds with longitudinal imaging and machine‑learning analyses to produce personalized multi‑organ toxicity profiles informing therapy decisions.
Scoring Rationale
Official cross‑company collaboration with experimental patient‑derived organoids drives translational relevance; limited novelty and narrow, pilot-scale scope.
Sources
- Read OriginaliXCells Biotechnologies joins international collaboration to evaluate chemotherapeutic toxicity in human organoidsnews-medical.net
